secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2026-09-16T12:00:53+00:00
Accession:  0000899923-26-000079
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad appoints Vishal Sikri EVP Commercial; CCO Brian Donnelly departs
-----------------------------------------------------------------------

- Brian Donnelly steps down as Chief Commercial Officer effective Sept 16, 2026; remains non-executive through Sept 21, 2026 for transition.
- Vishal Sikri promoted from SVP Product to EVP Commercial effective Sept 16, 2026.
- Sikri brings molecular diagnostics/oncology expertise and prior commercial leadership roles.
- Company reaffirms full-year 2026 financial guidance from July 30, 2026 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000079/0000899923-26-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000079/mygn-20260915.htm
  HTML page:      https://secwatch.observer/filing/0000899923-26-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer